Sort by
Refine Your Search
-
substantial opportunity to shape research direction and develop independent lines of investigation in an emerging area at the interface of microbiology, materials science, and electronics. Research Environment
-
. About GSK GSK is a focused biopharma company with strong momentum and big ambitions, to unite science, technology, and talent to get ahead of disease together. We aim to positively impact the health
-
economics, or outcomes research through prior research, coursework, or rotation experience Additional Information Applicants should submit the following application materials by the priority deadline
-
who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug
-
prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by “interfering” with mRNA
-
management plan, so we’re committed to continuous improvement in the way patients and professionals measure, track and analyze glucose levels. Our science-driven products empower people living with diabetes
-
Alnylam We are the leader in RNAi therapeutics – a revolutionary approach with the potential to transform the lives of people with rare and common diseases. Built on Nobel Prize-winning science, Alnylam has
-
are the leader in RNAi therapeutics – a revolutionary approach with the potential to transform the lives of people with rare and common diseases. Built on Nobel Prize-winning science, Alnylam has delivered
-
prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by “interfering” with mRNA
-
investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including IgA nephropathy, neuropathic pain, APOL1-mediated kidney disease